Tags

Type your tag names separated by a space and hit enter

Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Int J Antimicrob Agents. 2020 04; 55(4):105933.IJ

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Ko WC
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Rolain JM
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
Lee NY
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Chen PL
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Huang CT
Department of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Lee PI
Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Hsueh PR
Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.

MeSH

Adenosine MonophosphateAlanineAnimalsAntiviral AgentsBetacoronavirusCOVID-19Clinical Trials as TopicCoronavirus InfectionsDNA-Directed RNA PolymerasesHumansPandemicsPneumonia, ViralSARS-CoV-2

Pub Type(s)

Editorial

Language

eng

PubMed ID

32147516

Clinical Trial Links

Computed Tomography for COVID-19 Diagnosis

Citation

Ko, Wen-Chien, et al. "Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections." International Journal of Antimicrobial Agents, vol. 55, no. 4, 2020, p. 105933.
Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933.
Ko, W. C., Rolain, J. M., Lee, N. Y., Chen, P. L., Huang, C. T., Lee, P. I., & Hsueh, P. R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 55(4), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933
Ko WC, et al. Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections. Int J Antimicrob Agents. 2020;55(4):105933. PubMed PMID: 32147516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Arguments in favour of remdesivir for treating SARS-CoV-2 infections. AU - Ko,Wen-Chien, AU - Rolain,Jean-Marc, AU - Lee,Nan-Yao, AU - Chen,Po-Lin, AU - Huang,Ching-Tai, AU - Lee,Ping-Ing, AU - Hsueh,Po-Ren, Y1 - 2020/03/06/ PY - 2020/02/16/received PY - 2020/02/28/revised PY - 2020/3/10/pubmed PY - 2020/4/30/medline PY - 2020/3/10/entrez KW - Betacoronavirus KW - COVID-19 KW - Coronavirus disease 2019 KW - Remdesivir KW - SARS-CoV-2 KW - Wuhan pneumonia SP - 105933 EP - 105933 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 55 IS - 4 SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32147516/Arguments_in_favour_of_remdesivir_for_treating_SARS_CoV_2_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(20)30083-2 DB - PRIME DP - Unbound Medicine ER -